Developing first-in-class drugs for challenging conditions like hepatitis B, cancer, and autoimmune diseases just got a significant boost. Clinical stage biotech Drug Farm has successfully closed its Series B funding round, raising $55.0M.
The company's approach stands out by integrating advanced mouse genetics with artificial intelligence technologies, a platform it uses to identify and develop novel therapies. This latest capital infusion will support Drug Farm's ongoing efforts to advance its promising pipeline.
